Get the Stockscreener App
98.41
1.98%
1.91
After Hours:
98.41
Icon Plc stock is traded at $98.41, with a volume of 2.20M.
It is up +1.98% in the last 24 hours and down -46.11% over the past month.
Icon is a global late-stage contract research organization that provides drug development and clinical trial services to pharmaceutical, biotechnology, and medical-device firms. While the vast majority of its revenue comes from clinical research, Icon also offers ancillary services such as laboratory and imaging capabilities. The company is headquartered in Ireland.
See More
Previous Close:
$96.50
Open:
$94.85
24h Volume:
2.20M
Relative Volume:
1.33
Market Cap:
$7.51B
Revenue:
$8.10B
Net Income/Loss:
$599.48M
P/E Ratio:
13.30
EPS:
7.3969
Net Cash Flow:
$971.50M
1W Performance:
+22.89%
1M Performance:
-46.11%
6M Performance:
-45.22%
1Y Performance:
-48.56%
1-Day Range:
$92.59
$99.52
1-Week Range:
$81.31
$99.52
52-Week Range:
$66.57
$211.00
Icon Plc Stock (ICLR) Company Profile
Compare ICLR vs TMO, DHR, IDXX, A, WAT
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ICLR
Icon Plc
|
98.41 | 7.37B | 8.10B | 599.48M | 971.50M | 7.3969 |
|
TMO
Thermo Fisher Scientific Inc
|
515.12 | 192.95B | 44.56B | 6.73B | 6.29B | 17.74 |
|
DHR
Danaher Corp
|
211.25 | 147.43B | 24.57B | 3.60B | 5.25B | 5.0475 |
|
IDXX
Idexx Laboratories Inc
|
630.73 | 50.70B | 4.30B | 1.06B | 1.04B | 13.08 |
|
A
Agilent Technologies Inc
|
126.34 | 35.90B | 6.95B | 1.30B | 1.15B | 4.5696 |
|
WAT
Waters Corp
|
328.66 | 32.13B | 3.17B | 642.63M | 539.81M | 10.77 |
Icon Plc Stock (ICLR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-12-26 | Downgrade | BofA Securities | Neutral → Underperform |
| Feb-12-26 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Jan-08-26 | Downgrade | Truist | Buy → Hold |
| Dec-15-25 | Downgrade | BofA Securities | Buy → Neutral |
| Nov-13-25 | Initiated | BMO Capital Markets | Market Perform |
| Sep-09-25 | Downgrade | Jefferies | Buy → Hold |
| Sep-03-25 | Upgrade | Rothschild & Co Redburn | Neutral → Buy |
| Aug-21-25 | Downgrade | Citigroup | Buy → Neutral |
| Jul-24-25 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Apr-29-25 | Downgrade | JP Morgan | Overweight → Neutral |
| Apr-14-25 | Downgrade | TD Cowen | Buy → Hold |
| Apr-10-25 | Downgrade | Barclays | Overweight → Equal Weight |
| Mar-21-25 | Downgrade | Goldman | Buy → Neutral |
| Jan-07-25 | Initiated | RBC Capital Mkts | Outperform |
| Oct-24-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Oct-14-24 | Initiated | Redburn Atlantic | Neutral |
| Sep-18-24 | Initiated | Leerink Partners | Outperform |
| Jun-06-24 | Initiated | Goldman | Buy |
| Dec-15-23 | Initiated | Truist | Buy |
| Sep-13-23 | Initiated | TD Cowen | Outperform |
| Jan-17-23 | Upgrade | Barclays | Equal Weight → Overweight |
| Jan-13-23 | Upgrade | Barclays | Equal Weight → Overweight |
| Nov-09-22 | Upgrade | BofA Securities | Neutral → Buy |
| Sep-07-22 | Initiated | UBS | Buy |
| Aug-25-22 | Initiated | Credit Suisse | Neutral |
| May-24-22 | Initiated | Guggenheim | Buy |
| Apr-25-22 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Apr-12-22 | Upgrade | Deutsche Bank | Hold → Buy |
| Sep-27-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Aug-05-21 | Resumed | Credit Suisse | Outperform |
| Jul-23-21 | Upgrade | Citigroup | Neutral → Buy |
| Jul-14-21 | Initiated | Citigroup | Neutral |
| Apr-13-21 | Resumed | BofA Securities | Neutral |
| Apr-01-21 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-08-21 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Mar-03-21 | Initiated | Barclays | Equal Weight |
| Mar-01-21 | Upgrade | UBS | Neutral → Buy |
| Feb-26-21 | Upgrade | Truist | Hold → Buy |
| Jul-24-20 | Downgrade | BofA Securities | Buy → Neutral |
| Apr-20-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Mar-26-20 | Upgrade | Barclays | Equal Weight → Overweight |
| Mar-02-20 | Initiated | Deutsche Bank | Hold |
| Jan-27-20 | Downgrade | SunTrust | Buy → Hold |
| Jan-08-20 | Initiated | Wells Fargo | Equal Weight |
| Jan-07-20 | Initiated | Citigroup | Neutral |
| Sep-23-19 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
| Jul-26-19 | Upgrade | UBS | Sell → Neutral |
| Jan-25-19 | Upgrade | Mizuho | Neutral → Buy |
| Oct-26-18 | Upgrade | Evercore ISI | In-line → Outperform |
| Oct-09-18 | Initiated | UBS | Sell |
| Apr-03-18 | Downgrade | Evercore ISI | Outperform → In-line |
| Feb-15-18 | Reiterated | Mizuho | Neutral |
| Jan-19-18 | Initiated | Evercore ISI | Outperform |
| Oct-27-17 | Reiterated | Barclays | Equal Weight |
| Sep-11-17 | Initiated | BofA/Merrill | Buy |
| Jul-31-17 | Upgrade | SunTrust | Hold → Buy |
| Jul-27-17 | Reiterated | Mizuho | Neutral |
| Jun-29-17 | Upgrade | Jefferies | Hold → Buy |
View All
Icon Plc Stock (ICLR) Latest News
73,467 Shares in Icon Plc $ICLR Purchased by Muhlenkamp & Co. Inc. - MarketBeat
TD Cowen upgrades ICON stock on valuation after accounting probe By Investing.com - Investing.com Nigeria
ICON INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is - GlobeNewswire
Icon plc: Accounting Probe Sell-Off Creates Compelling Value Despite Modest EPS Impact - TipRanks
2026-02-18 | Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against ICON plc (ICLR) and Encourages Investors to Learn More About the Investigation | NDAQ:ICLR | Press Release - Stockhouse
ICON plc Faces Investigation After Internal Probe Reveals Multi-Year Revenue Overstatement - GuruFocus
FDA Grants Breakthrough Status To Johnson & Johnson's Cancer Drug For Advanced Head and Neck Cancer - Benzinga
TD Cowen upgrades ICON stock on valuation after accounting probe - Investing.com
Icon Plc $ICLR Shares Sold by Eagle Health Investments LP - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against ICON plc (ICLR) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
ICON Faces Investor Lawsuit Investigation - Intellectia AI
ICON (ICLR) stock slides as Rothschild Redburn cuts rating, extending pressure from accounting probe - Bez Kabli
Icon PLC headcount plummets 1,800 in a year amid ‘strong cost control’ - MSN
ICLR ALERT: Securities Fraud Investigation by Block & Leviton Could Allow ICON pcl Investors to Recover Losses - TradingView
Rothschild downgrades ICON stock on accounting investigation By Investing.com - Investing.com
ICON plc (ICLR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
ICON plc (ICLR) Stock Analysis: Unveiling an 87.74% Potential Upside in Healthcare Diagnostics - DirectorsTalk Interviews
Clinical Research Provider Icon Stock Crashes On Accounting Probe - AOL.com
ICON (ICLR) Is Down 38.2% After Internal Revenue Probe And Pulled 2025 OutlookWhat's Changed - simplywall.st
Market briefs: ECB extends interest rate pause and Birkenstock misses estimate - Business Post
ICON Public Limited Company (ICLR) Delays Earnings Amid Internal Investigation - Finviz
Icon’s Price Target Revisions Amid Strategic Expansions and New Partnerships - timothysykes.com
US law firms circle Icon PLC after revelations of accounting probe send shares plunging - The Irish Independent
ICON PLC (ICON) soars 16% as analyst issues 'hold', $93 PT despite accounting concerns - MSN
ICON PLC (ICON) Soars 16% as Analyst Issues 'Hold', $93 PT Despite Accounting Concerns - Finviz
ICON PLC (ICON) Soars 16% as Analyst Issues ‘Hold’, $93 PT Despite Accounting Concerns - Insider Monkey
ICON plc (ICLR) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
ICON (ICLR) stock rebounds after accounting probe shock — what investors watch next - Bez Kabli
ICON plc Expands Oncology Research, Sets New Price Target - StocksToTrade
Icon Strategy Expands with New Partnership to Bolster Oncology Research - timothysykes.com
ICON Expands Oncology Research Capabilities Amidst Positive Stock Reevaluation - StocksToTrade
ICON plc Expands Clinical Trial Capabilities through Strategic Partnership - timothysykes.com
Icon Partners with Brian Moran for Key Oncology Expansion - StocksToTrade
ICON plc Expands Oncology Network, Stock Assessment and Market Analysis - timothysykes.com
ICON plc Expands Oncology Research, Price Target Upgraded - StocksToTrade
ICON plc (ICLR) Shares Crater Amid Delayed Financial Report, Investigation Into Revenue Recognition IssuesHagens Berman - The Malaysian Reserve
ICON (ICLR) Is Down 44.9% After Probing Revenue Recognition And Control WeaknessesWhat's Changed - Yahoo Finance
Truist Financial Maintains Icon PLC(ICLR.US) With Hold Rating - 富途牛牛
ICON plc (ICLR) Shares Crater Amid Delayed Financial Report, Inv - GuruFocus
ICON (ICLR) stock steadies premarket after 40% crash on accounting probe — what’s next - Bez Kabli
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against ICON plc (ICLR) And Encourages Investors to Reach Out - ACCESS Newswire
Icon PLC stock hits 52-week low at $79.49 By Investing.com - Investing.com Australia
Here's How Much $100 Invested In Icon 20 Years Ago Would Be Worth Today - Sahm
ICON stock plummets after accounting investigation delays earnings By Investing.com - Investing.com
ICON stock rating suspended by Evercore amid accounting investigation By Investing.com - Investing.com Canada
ICON stock rating downgraded by BofA Securities amid accounting concerns - Investing.com UK
Ademi LLP Investigates Claims of Securities Fraud against ICON plc - The Malaysian Reserve
ICON Public Limited Company Under Investigation for Securities Law Violations - Intellectia AI
ICON plc Shares Plunge 49% Amid Revenue Recognition Investigation - Intellectia AI
ICON plc (ICLR) Shares Crater Amid Delayed Financial - GlobeNewswire
Medtech Plummets 40% On Profit-Threatening Investigation - Investor's Business Daily
Icon Plc Stock (ICLR) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.95%
1.33%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):